DJ-1 is a reliable serum biomarker for discriminating high-risk endometrial cancer

Tumor Biology

Volumn 39, Issue 6, 2017, Pages

  Di Cello, Annalisa ^a   Di Sanzo, Maddalena ^a   Perrone, Francesca Marta ^a   Santamaria, Gianluca ^a   Rania, Erika ^a   Angotti, Elvira ^b   Venturella, Roberta ^a   Mancuso, Serafina ^b   Zullo, Fulvio ^a   Cuda, Giovanni ^a   Costanzo, Francesco ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b Department of Anesthesia and Intensive Care   (Italy)

Author keywords

Differential diagnosis; DJ 1; Endometrial cancer; Pre operative risk stratification; Serum biomarker

Indexed keywords

PROTEIN DEGLYCASE DJ-1; PARK7 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; DISEASE EXACERBATION; ENDOMETRIUM CANCER; FEMALE; HIGH RISK PATIENT; HUMAN; LOW RISK PATIENT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; BLOOD; ENDOMETRIUM TUMOR; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADULT; AGED; BIOMARKERS, TUMOR; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; PROGNOSIS; PROTEIN DEGLYCASE DJ-1;

EID: 85025138208     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1177/1010428317705746     Document Type: Article

References (41)

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwidwe: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: 359-386.
2. ESMO guidelines, http://www.esmo.org/Guidelines/ Gynaecological-Cancers/Endometrial-Cancer
3. National Cancer Institute. Comprehensive cancer information, http://www.cancer.gov/
4. Creasman WT, Kohler MF, Odicino F, et al. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol Oncol 2004; 95: 593-596.
5. Matsuo K, Opper NR, Ciccone MA, et al. Time interval between endometrial biopsy and surgical staging for type I endometrial cancer: association between tumor characteristics and survival outcome. Obstet Gynecol 2015; 125: 424-433.
6. Di Cello A, Rania E, Zuccalà V, et al. Failure to recognize preoperatively high-risk endometrial carcinoma is associated with a poor outcome. Eur J Obstet Gynecol Reprod Biol 2015; 194: 153-160.
7. Body N, Lavouè V, De Kerdaniel O, et al. Are preoperative histology and MRI useful for classification of endometrial cancer risk? BMC Cancer 2016; 16: 498.
8. Alcazar JL, Dominguez-Piriz J, Juez L, et al. Intraoperative gross examination and intraoperative frozen section in patients with endometrial cancer for detecting deep myometrial invasion: a systematic review and meta-analysis. Int J Cancer Gynecol 2016; 2: 407-415.
9. Dai D, Thiel KW, Salinas EA, et al. Stratification of endometrioid endometrial cancer patients into risk levels using somatic mutations. Gynecol Oncol 2016; 142: 150-157.
10. McAlpine JN, Temkin SM and Mackay HJ. Endometrial cancer: not your grandmother’s cancer. Cancer 2016; 122: 2787-2798.
11. Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497: 67-73.
12. Morelli M, Scumaci D, Di Cello A, et al. DJ-1 in endometrial cancer: a possible biomarker to improve differential diagnosis between subtypes. Int J Gynecol Cancer 2014; 24: 649-658.
13. Cao J, Lou S, Ying M, et al. DJ-1 as a human oncogene and potential therapeutic target. Biochem Pharmacol 2015; 93: 241-250.
14. Bande MF, Santiago M, Blanco MJ, et al. Serum DJ-1/ PARK 7 is a potential biomarker of choroidal nevi transformation. Invest Ophthalmol Vis Sci 2012; 53: 62-67.
15. Chen LL, Tian JJ, Su L, et al. DJ-1: a promising marker in metastatic uveal melanoma. J Cancer Res Clin Oncol 2015; 141: 315-321.
16. He X, Zheng Z, Li J, et al. DJ-1 promotes invasion and metastasis of pancreatic cancer cells by activating SRC/ ERK/uPA. Carcinogenesis 2012; 33: 555-562.
17. Ismail IA, Kang HS, Lee HJ, et al. DJ-1 upregulates breast cancer cell invasion by repressing KLF17 expression. Br J Cancer 2014; 110: 1298-1306.
18. Shu K, Xiao Z, Long S, et al. Expression of DJ-1 in endometrial cancer: close correlation with clinicopathological features and apoptosis. Int J Gynecol Cancer 2013; 23: 1029-1035.
19. R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, 2015.
20. Sing T, Sander O, Beerenwinkel N, et al. ROCR: visualizing classifier performance in R. Bioinformatics 2005; 21: 3940-3941.
21. NCCN uterine neoplasms guidelines 2016, https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf
22. Li X, Gao Y, Tan M, et al. Expression of HE4 in endometrial cancer and its clinical significance. Biomed Res Int 2015; 437-468.
23. Angioli R, Capriglione S, Scaletta G, et al. The role of HE4 in endometrial cancer recurrence: how to choose the optimal follow-up program. Tumor Biol 2016; 37: 4973-4978.
24. Hu L, Du S, Guo W, et al. Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in endometrial cancer: a meta-analysis. Int J Gynecol Cancer 2016; 26: 331-340.
25. Bai J, Guo C, Sun W, et al. DJ-1 may contribute to metastasis of non-small cell lung cancer. Mol Biol Rep 2012; 39: 2697-2703.
26. Davidson B, Hadar R, Schlossberg A, et al. Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma. Hum Pathol 2008; 39: 87-95.
27. Schumann C, Chan S, Khalimonchuk O, et al. Mechanistic nanotherapeutic approach based on siRNA-mediated DJ-1 protein suppression for platinum-resistant ovarian cancer. Mol Pharm 2016; 13: 2070-2083.
28. Yuen HF, Chan YP, Law S, et al. DJ-1 could predict worse prognosis in esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2008; 17: 3593-3602.
29. Kawate T, Iwaya K, Koshikawa K, et al. High levels of DJ-1 protein and isoelectric point 6.3 isoform in sera of breast cancer patients. Cancer Sci 2015; 106: 938-943.
30. Pylväs-Eerola M, Karihtala P and Puistola U. Preoperative serum 8-hydroxydeoxyguanosine is associated with chemoresistance and is a powerful prognostic factor in endometrioidtype epithelial ovarian cancer. BMC Cancer 2015; 15: 493.
31. Park JY, Nam JH, Kim YT, et al. Poor prognosis of uterine serous carcinoma compared with grade 3 endometrioid carcinoma in early stage patients. Virchows Arch 2013; 462: 289-296.
32. Voss MA, Ganesan R, Ludeman L, et al. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer—a clinical and pathological evaluation. Gynecol Oncol 2012; 124: 15-20.
33. Zannoni GF, Scambia G and Gallo D. The dualistic model of endometrial cancer: the challenge of classifying grade 3 endometrioid carcinoma. Gynecol Oncol 2012; 127: 262-263.
34. Zannoni GF, Vellone VG, Arena V, et al. Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical-pathological and immunohistochemical study. Virchows Arch 2010; 457: 27-34.
35. Meng B, Hoang LN, McIntyre JB, et al. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium. Gynecol Oncol 2014; 134: 15-19.
36. Church DN, Stelloo E, Nout RA, et al. Prognostic significance of POLE proofreading mutations in endometrial cancer. J Natl Cancer Inst 2014; 107: 402.
37. Growdon WB, Groeneweg J, Byron V, et al. HER2 overexpressing high grade endometrial cancer expresses high levels of p95HER2 variant. Gynecol Oncol 2015; 137: 160-166.
38. Liu Y, Broaddus RR and Zhang W. Identifying aggressive forms of endometrioid-type endometrial cancer: new insights into molecular subtyping. Expert Rev Anticancer Ther 2015; 15: 1-3.
39. Zhuang J, Faggiano P, Li Q, et al. Insights into the clinical implications of carbohydrate antigen 125 as a biomarker of heart failure: a meta-analysis and systematic review of published studies. Cardiovasc Med 2014; 15: 864-872.
40. Durak-Nalbantic A, Resic N, Kulic M, et al. Serum level of tumor marker carbohydrate antigen-CA125 in heart failure. Med Arch 2013; 67: 241-244.
41. Vizzardi E, D’Aloia A, Curnis A, et al. Carbohydrate antigen 125: a new biomarker in heart failure. Cardiol Rev 2013; 21: 23-26.